Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99.

CAS  PubMed  Article  Google Scholar 

Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology. 2020;95:e2610–21.

CAS  PubMed  Article  Google Scholar 

Heaton RK, Franklin DR Jr, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60:473–80.

CAS  PubMed  Article  Google Scholar 

• Chan P, Kerr SJ, Kroon E, et al. Cognitive trajectories after treatment in acute HIV infection. AIDS. 2021;35(6):883–8. https://doi.org/10.1097/QAD.0000000000002831. Immediate suppressive ART in AHI improves and sustains cognitive function in multiple domains for up to 6 years, with the largest improvements in patients with the poorest baseline cognitive functioning. Provides support for earliest possible intervention with cART, and suggests possible window of opportunity for early adjunctive therapies.

• Bougea A, Spantideas N, Galanis P, et al. Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review. Ther Adv Infect Dis. 2019;6:2049936119838228. This is an up-to-date, comprehensive review that adds important perspective to treatment of HIV-NCI.

Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13:1139–51.

CAS  PubMed  PubMed Central  Article  Google Scholar 

•• Lin SP, Calcagno A, Letendre SL, et al. Clinical treatment options and randomized clinical trials for neurocognitive complications of HIV infection: combination antiretroviral therapy, central nervous system penetration effectiveness, and adjuvants. Curr Top Behav Neurosci. 2021;50:517–545. A very comprehensive review of cross-sectional, prospective, and randomized controlled trials of CPE-rated regimens in HIV-NCI.

Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33–44.

CAS  PubMed  Article  Google Scholar 

Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17:1233–42.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230–8.

PubMed  PubMed Central  Article  Google Scholar 

Chen MF, Gill AJ, Kolson DL. Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism. Curr Opin HIV AIDS. 2014;9:559–64.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819–25.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.

PubMed  PubMed Central  Article  Google Scholar 

Cusini A, Vernazza PL, Yerly S, et al. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2013;62:28–35.

CAS  PubMed  Article  Google Scholar 

Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204:1936–45.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17:355–64.

CAS  PubMed  Article  Google Scholar 

•• Force G, Ghout I, Ropers J, et al. Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. J Antimicrob Chemother. 2021;76:743–752. A relatively small (n=49 patients), but well-designed prospective ART intensification study of several different CPE-based ART regimens.

Dou H, Grotepas CB, McMillan JM, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol. 2009;183:661–9.

CAS  PubMed  Article  Google Scholar 

Gomes MJ, Neves J, Sarmento B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed. 2014;9:1757–69.

Google Scholar 

Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4:557–74.

CAS  Article  Google Scholar 

Edagwa B, McMillan J, Sillman B, et al. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017;14:1281–91.

CAS  PubMed  PubMed Central  Article  Google Scholar 

McMillan J, Szlachetka A, Slack L, et al. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob Agents Chemother. 2017;62(1):e01316–17. https://doi.org/10.1128/AAC.01316-17.

Ndhlovu LC, Umaki T, Chew GM, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014;20:571–82.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gates TM, Cysique LA, Siefried KJ, et al. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS. 2016;30:591–600.

CAS  PubMed  Article  Google Scholar 

•• Martin-Blondel G, Brassat D, Bauer J, et al. CCR5 blockade for neuroinflammatory diseases--beyond control of HIV. Nat Rev Neurol. 2016;12:95–105. This thought-provoking review presents a thorough insight into the multiple potential mechanisms through which CCR5 blockade could provide neuroprotection in both infectious and non-infectious neuroinflammatory diseases.

Leon-Rivera R, Veenstra M, Donoso M, et al. Central nervous system (CNS) viral seeding by mature monocytes and potential therapies to reduce CNS viral reservoirs in the cART era. mBio. 2021;12(2):e03633–20. https://doi.org/10.1128/mBio.03633-20.

Williams DW, Veenstra M, Gaskill PJ, et al. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res. 2014;12:85–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

• D'Antoni ML, Paul RH, Mitchell BI, et al. Improved cognitive performance and reduced monocyte activation in virally suppressed chronic HIV after dual CCR2 and CCR5 antagonism. J Acquir Immune Defic Syndr. 2018;79:108–116. An open-label 24-week study demonstrating improved NP test performance and reduced monocyte activation in virally suppressed patients treated with cenicriviroc.

•• Christensen BL, Tan DH. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. Expert Opin Pharmacother. 2022;23:439–446. A truly comprehensive up-to-date summary of DTG/ABC/3TC efficacy and where this regimen stands as a first-line treatment for HIV.

• Diggins CE, Russo SC, Lo J. Metabolic consequences of antiretroviral therapy. Curr HIV/AIDS Rep. 2022;19(2):141–53. https://doi.org/10.1007/s11904-022-00600-6. A very useful review of adverse metabolic effects of current ART regimens

• O'Halloran JA, Cooley SA, Strain JF, et al. Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors. AIDS. 2019;33:1477–1483. A large (n=202 patients), provocative cross-sectional neuroimaging study suggesting reduced brain integrity in INSTI users.

• Prats A, Martinez-Zalacain I, Mothe B, et al. Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection. Sci Rep. 2021;11:11289. A prospective, controlled study of men LWH with matched seronegative controls. INSTI initiation before 3 months or later than 6 months after HIV infection associated with no cognitive differences, but with less loss of brain integrity.

•• Chan P, Goh O, Kroon E, et al. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Res Ther. 2020;17:1. A large (n = 254) AHI patients in the RV254 Thai cohort that suggests depressive symptoms associate with DTG use.

Lanman T, Letendre S, Ma Q, et al. CNS neurotoxicity of antiretrovirals. J Neuroimmune Pharmacol. 2019;16(1):130–43. https://doi.org/10.1007/s11481-019-09886-7.

Article  Google Scholar 

Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18:388–99.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359–66.

PubMed  Article  Google Scholar 

•• Pereira GFM, Kim A, Jalil EM, et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8:e33-e41. An important, large retrospective outcomes study of DTG use in pregnancy, demonstrating no DTG risk for neural tube defects.

•• Abrams E, Myer L. Lessons from dolutegravir and neural tube defects. Lancet HIV. 2021;8:e3-e4. A commentary that convincingly argues in favor of the benefits of DTG use during pregnancy.

Uzasci L, Nath A, Cotter R. Oxidative stress and the HIV-infected brain proteome. J Neuroimmune Pharmacol. 2013;8:1167–80.

PubMed  Article  Google Scholar 

McArthur JC, Johnson TP. Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies. Curr Opin Neurol. 2020;33:397–404.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.

CAS  PubMed  Article  Google Scholar 

Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE. 2008;3:e2516.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Price RW, Spudich SS, Peterson J, et al. Evolving character of chronic central nervous system HIV infection. Semin Neurol. 2014;34:7–13.

PubMed  PubMed Central  Article  Google Scholar 

Stam AJ, Nijhuis M, van den Bergh WM, et al. Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Rev. 2013;15:152–61.

PubMed  Google Scholar 

Biswas SK. Does the Interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid Med Cell Longev. 2016;2016:5698931.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Mollace V, Nottet HS, Clayette P, et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci. 2001;24:411–6.

CAS  PubMed  Article  Google Scholar 

Valcour V, Shiramizu B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion. 2004;4:119–29.

CAS  PubMed  Article  Google Scholar 

Malvy DJ, Richard MJ, Arnaud J, et al. Relationship of plasma malondialdehyde, vitamin E and antioxidant micronutrients to human immunodeficiency virus-1 seropositivity. Clin Chim Acta. 1994;224:89–94.

CAS  PubMed  Article